BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.

[1]  M. Hirokawa,et al.  BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. , 2009, Endocrine journal.

[2]  A. Pinchera,et al.  BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.

[3]  M. Xing,et al.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. , 2007, Endocrine reviews.

[4]  M. Santoro,et al.  Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.

[5]  Electron Kebebew,et al.  The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer , 2007, Annals of surgery.

[6]  S. Filetti,et al.  BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. , 2007, The Journal of clinical endocrinology and metabolism.

[7]  B. Lang,et al.  Staging Systems for Papillary Thyroid Carcinoma: A Study of 2 Tertiary Referral Centers , 2007, Annals of surgery.

[8]  Ju-Han Lee,et al.  Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid , 2007, Cancer.

[9]  S. Sidhu,et al.  Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. , 2006, Surgery.

[10]  Tae Yong Kim,et al.  The BRAF mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinoma , 2006, Clinical endocrinology.

[11]  M. A. García-Cabezas,et al.  The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. , 2006, Endocrine-related cancer.

[12]  T. Giordano,et al.  Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas , 2006, The American journal of surgical pathology.

[13]  P. Ladenson,et al.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[14]  O. Clark,et al.  Papillary thyroid cancer: Surgical management of lymph node metastases , 2005, Current treatment options in oncology.

[15]  G. Thomas,et al.  Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure , 2005, The Journal of pathology.

[16]  André Aurengo,et al.  Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.

[17]  P. Beck‐Peccoz,et al.  BRAF mutations in an Italian cohort of thyroid cancers , 2004, Clinical endocrinology.

[18]  A. Pinchera,et al.  BRAFV599E Mutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas , 2004 .

[19]  M. Nikiforova,et al.  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[20]  H. Namba,et al.  Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.

[21]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[22]  I. Sugitani,et al.  Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. , 2008, Surgery.

[23]  L. Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.